NASDAQ: BNOX - Bionomics Limited

Yield per half year: -34.95%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Bionomics Limited

Extended chart Simple chart
Financial Markets by TradingView

About Bionomics Limited

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

more details
It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-12-16
ISIN US09063M2052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.bionomics.com.au
Цена ао 5.01
Change price per day: 0% (5.01)
Change price per week: 0% (5.01)
Change price per month: +8.91% (4.6)
Change price per 3 month: +46.44% (3.4212)
Change price per half year: -34.95% (7.7016)
Change price per year: +381.73% (1.04)
Change price per 3 year: -46.07% (9.29)
Change price per 5 year: 0% (5.01)
Change price per 10 year: 0% (5.01)
Change price per year to date: +64.95% (3.0372)
All parameters

Underestimation

Title Value Grade
P/S 4290.29 1
P/BV 4.91 3
P/E 0 0
EV/EBITDA -7.47 0
Total: 2.88

Efficiency

Title Value Grade
ROA, % -66284.99 0
ROE, % -117366.73 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0278 10
Total: 9.4

Growth impulse

Title Value Grade
Yield Revenue, % -98.45 0
Yield Ebitda, % 272.62 10
Yield EPS, % 74740506.06 10
Total: 8
More

Institutions Volume Share, %
Lynx1 Capital Management Lp 824305 10.1
Point72 Asset Management, L.P. 331000 4.06
Morgan Stanley 94967 1.16
Two Sigma Investments, LP 31272 0.38
XTX Topco Ltd 11834 0.15
Tower Research Capital LLC (TRC) 1606 0.02
Rhumbline Advisers 505 0.01
UBS Group AG 329 0
Aspire Private Capital, LLC 200 0



Head Job title Payment Year of birth
Dr. Spyridon Papapetropoulos M.D., Ph.D. CEO, President & Director 510.37k 1973 (52 years)
Mr. Timothy M. Cunningham CPA, M.B.A. Chief Financial Officer N/A 1963 (62 years)
Dr. Julie Kerner Ph.D. Senior Vice President of Business Operations N/A
Ms. Elizabeth Doolin Senior Vice President of Clinical Development 1965 (60 years)
Dr. Mark A. Smith M.D., Ph.D. Chief Medical Officer 1955 (70 years)

Address: Australia, Eastwood, 200 Greenhill Road - open in Google maps, open in Yandex maps
Website: https://www.bionomics.com.au